

## Press Release

### **Revenue up by 21% and PAT up by 18%** (4<sup>th</sup> Quarter FY 2026 Consolidated Results)

**Mumbai, 5<sup>th</sup> May, 2026:** Ajanta Pharma Ltd., a specialty pharmaceutical formulation company today reported its excellent performance for 4<sup>th</sup> quarter and year ended 31<sup>st</sup> March 2026.

#### Q4 FY 2026 performance highlights (compared to Q4 FY 2025):

- Revenue from operations at **Rs. 1,422 cr.** against Rs. 1,170 cr.; **up 21%**.
- EBITDA at **Rs. 333 cr.** against Rs. 297 cr.; EBITDA at 23%; **up 12%**.
- The mark-to-market forex loss stood at Rs. 42 cr. Excluding this impact, EBITDA stood at **Rs. 375 cr.**, reflecting a 26% growth, with an **EBITDA margin of 26%**.
- Profit after tax at **Rs. 267 cr.** against Rs. 225 cr.; PAT at 19%; **up 18%**.

#### FY 2026 performance highlights (compared to FY 2025):

- Revenue from operations at **Rs. 5,453 cr.** against Rs. 4,648 cr.; **up 17%**.
- EBITDA at **Rs. 1,395 cr.** against Rs. 1,260 cr.; EBITDA at 26%; **up 11%**.
- The mark-to-market forex loss stood at Rs. 103 cr. Excluding this impact, EBITDA stood at **Rs. 1,498 cr.**, reflecting a 18% growth, with an **EBITDA margin of 27%**.
- Profit after tax at **Rs. 1,056 cr.** against Rs. 920 cr.; PAT at 19%; **up 15%**.
- ROCE stood at a healthy level of 33% and RONW at 25%.

#### Segment wise performance:

(Rs. cr.)

Markets	Q4		Gwth%	FY		Gwth%
	FY 2025	FY 2026		FY 2025	FY 2026	
Branded Generics						
India	₹ 369	₹ 404	9%	₹ 1,452	₹ 1,654	14%
Asia	₹ 303	₹ 274	(10%)	₹ 1,191	₹ 1,175	(1%)
Africa	₹ 133	₹ 182	37%	₹ 750	₹ 861	15%
<b>Sub-Total</b>	<b>₹ 805</b>	<b>₹ 859</b>	<b>7%</b>	<b>₹ 3,394</b>	<b>₹ 3,690</b>	<b>9%</b>
<b>US Generic</b>	<b>₹ 325</b>	<b>₹ 505</b>	<b>56%</b>	<b>₹ 1,047</b>	<b>₹ 1,557</b>	<b>49%</b>
<b>Africa Institution</b>	<b>₹ 28</b>	<b>₹ 48</b>	<b>71%</b>	<b>₹ 147</b>	<b>₹ 160</b>	<b>9%</b>
<b>Total</b>	<b>₹ 1,158</b>	<b>₹ 1,412</b>	<b>22%</b>	<b>₹ 4,588</b>	<b>₹ 5,407</b>	<b>18%</b>

As per **IQVIA MAT March 2026**, our India branded generic performance exceeded IPM growth by **33%**. The higher growth came from new launches, which exceeded IPM by **68%** & volumes, which exceeded IPM by **34%**.

Therapy	Growth %	
	IPM	Ajanta
Cardiology	14%	7%
Ophthalmology	9%	14%
Dermatology	7%	14%
Pain Management	8%	12%
<b>Overall</b>	<b>10%</b>	<b>13%</b>

**ANDA status** as at the end of FY 2026 is as below:

Particulars	FY 2026
Filed	5
Approval received	4
Launched	4
Total ANDA's commercialized	49
Awaiting approval with US FDA	19
Tentative approval	6

**R&D expense:**

(Rs. cr.)

Particulars	FY 2025	FY 2026	% to Revenue
Q4	₹ 53	₹ 70	5%
FY	₹ 161	₹ 252	5%

### About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 30+ countries. Many of company's products are 1<sup>st</sup> to market and are leading in their sub-therapeutic segments. Company also has presence in USA in generic business and institution business in Africa.

Company's state of the art R&D centre is in Mumbai. Company has 7 world class manufacturing facilities located in India.

For the last 3 financial years, company has posted healthy Revenue and PAT CAGR of 14%.

## **Earnings Conference Call**

The Company will host an Earnings Conference Call at 16:30 hrs. IST (19:00 hrs. SST/HKT, 12:00 hrs. BST, 07:00 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at [www.ajantapharma.com](http://www.ajantapharma.com).

## **Dial-in Information**

<b>Date and Time</b>	<b>May 05, 2026 at</b> 16:30 – 17:30 hrs IST 19:00 – 20:00 hrs SST/HKT 12:00 – 13:00 hrs BST 07:00 – 08:00 hrs US ET
<b>Dial-in Numbers</b>	
<b>Diamond pass link for faster access</b>	Click <a href="#">here</a> to register
Universal Access	Primary Access: <b>(+91 22 6280 1542)</b> <b>(+91 22 7115 8372)</b>
International Toll Free	USA: <b>18667462133</b> UK: <b>08081011573</b> Hong Kong: <b>800964448</b> Singapore: <b>8001012045</b>

### **For convenience and faster connectivity to the conference, kindly follow below steps:**

1. Register through the Diamond pass link.
2. You will receive a calendar invite along with a passcode and a PIN number. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time.
3. Dial the 'conference Dial-in number' you will receive on your email.
4. On system prompt dial the PASSCODE followed by # key.
5. On system prompt enter the PIN followed by # key.
6. If the line gets disconnected, you need to dial the 'conference dial-in number' again and follow the necessary steps.

### **Playback of Earnings Conference Call audio:**

Playback of the earnings call will be available 120 minutes after the end of the call on our website ([www.ajantapharma.com](http://www.ajantapharma.com)).

For more details visit [www.ajantapharma.com](http://www.ajantapharma.com)

For regular updates follow us on x.com – <https://x.com/AjantaPharmaLtd>

### **For specific queries, contact:**

**Rajeev Agarwal** Tel: +91 22 6060 9706 Email: [rajeev.agarwal@ajantapharma.com](mailto:rajeev.agarwal@ajantapharma.com)

**Abhineet Kumar** Tel: +91 22 6060 9721 Email: [abhineet.kumar@ajantapharma.com](mailto:abhineet.kumar@ajantapharma.com)

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Corporate Identity Number (CIN): L24230M9M979PLC022059

### **Safe Harbour Statement**